SEARCH

SEARCH BY CITATION

References

  • Banner, D.W., D'Arcy, A., Chène, C., Winkler, F.K., Guha, A., Konigsberg, W.H., Nemerson, Y. & Kirchhofer, D. (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature, 380, 4146.
  • Bauer, K.A. (1996) Treatment of factor VII deficiency with recombinant factor VIIa. Haemostasis, 26(Suppl. 1), 155158.
  • Berrettini, M., Mariani, G., Schiavoni, M., Rocino, A., Di Paolantonio, T., Longo, G. & Morfini, M. (2001) Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica, 86, 640645.
  • Charpiat, B., Laporte, S., Mismetti, P., Debize, G. & Ducerf, C. (2002) Perioperative pharmacokinetics of factor VII concentrate during liver surgery in a patient with congenital factor VII deficiency: an individual mathematical model. Blood Coagulation and Fibrinolysis, 13, 457460.
  • Eskandari, N., Feldman, N. & Greenspoon, J.S. (2002) Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstetrics and Gynecology, 99, 935937.
  • Giansily-Blaizot, M., Aguilar-Martinez, P. & Schved, J.F. (2002) Genotypic heterogeneity may explain phenotypic variations in inherited factor VII deficiency. Haematologica, 87, 328329.
  • Hedner, U. (2003) Recombinant factor VIIa (NovoSeven®) as a hemostatic agent. Disease-a-Month, 49, 3948.
  • Hunault, M. & Bauer, K.A. (2000) Recombinant factor VIIa for the treatment of congenital factor VII deficiency. Seminars in Thrombosis and Haemostasis, 26, 401405.
  • Ingerslev, J., Knudsen, L., Hvid, I., Tange, M.R., Fredberg, U. & Sneppen, O. (1997) Use of recombinant factor VIIa in surgery in factor-VII-deficient patients. Haemophilia, 3, 215218.
  • Lindley, C.M., Sawyer, W.T., Macik, B.G., Lusher, J., Harrison, J.F., Bairdcox, K., Birch, K., Glazer, S. & Roberts, H.R. (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clinical Pharmacology and Therapeutics, 55, 638648.
  • Lund-Hansen, T. (1996) NovoSeven®– virus safety. Haemostasis, 26(Suppl. 1), 9697.
  • Mariani, G., Testa, M.G., Di Paolantonio, T., Molskov Bech, R. & Hedner, U. (1999) Use of recombinant activated factor VII in the treatment of congenital factor VII deficiencies. Vox Sanguinis, 77, 131136.
  • Perry, D.J. (2002) Factor VII deficiency. British Journal of Haematology, 118, 689700.
  • Roberts, H.R. (2001) Recombinant factor VIIa (NovoSeven®) and the safety of treatment. Seminars in Hematology, 38(Suppl. 12), 4850.
  • Saxon, B.R., Shanks, D., Jory, C.B. & Williams, V. (2001) Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-NovoSeven) in a child with high titre inhibitors and a target joint. Thrombosis and Haemostasis, 86, 11261127.
  • Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., Van den Berg, M. & Mauser-Bunschoten, E. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis, 73, 247251.
  • Wilde, J.T. (2002) Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors. Pathophysiology of Haemostasis and Thrombosis, 32(Suppl. 1), 912.
  • Wildgoose, P., Nemerson, Y., Lyng Hansen, L., Nielsen, F.E., Glaxer, S. & Hedner, U. (1992) Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood, 80, 2528.